USP22

Across TCGA pan-cancer cohorts, USP22 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated USP22 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher USP22 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP22 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, UCEC, and LSCC are the cancer types where USP22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.659	0.949	.001	45	view →
UCEC	DFS	Quartile	All	0.832	1.000	.002	10	view →
LSCC	OS	Tertile	All	1.000	0.940	.028	5	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
GBM	DFS	Tertile	All	0.491	0.292	.043	3	view →
CCRCC	OS	Median	All	0.694	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

USP22–HNSC (DFS)

Open the HNSC breakdown →